Clinical Professor of Medicine, NYU Langone Health and Senior Medical Director Clinical Sciences, Global Development, Regeneron
NYU Langone Health & Regeneron
Short Hills, NJ, United States
Ramachandra G. Naik, MD, DM, is a US board-certified endocrinologist with over three decades of global experience in patient care, clinical research and drug development, currently working at NYU Langone Health, serving as a clinical professor of medicine and Director, Diabetes Clinical Research, in the Division of Endocrinology, Diabetes and Metabolism at NYU Grossman School of Medicine, New York, NY.
Dr. Naik completed his endocrinology fellowship and board certifications from All India Institute of Medical Sciences, New Delhi, India, and later pursued an additional fellowship program at the University of Washington, Seattle, WA. He was a recipient of Juvenile Diabetes Research Foundation post-doctoral fellowship award at the University of Washington.
Dr. Naik spent more than a decade of his professional career, as a consultant endocrinologist, at Bombay Hospital in Mumbai, India. He relocated to the United States in 2007 to join as a faculty at the Barbara Davis Center for Childhood Diabetes, University of Colorado Denver. Dr. Naik transitioned into biopharmaceutical industry in 2009 and spent the next eight years in roles of progressively increasing responsibility, providing clinical leadership in global drug development in diabetes and endocrinology, at Novartis, Merck, and J&J, and also serving as an adjunct associate professor of medicine at the University of Pennsylvania Perelman School of Medicine.
Dr. Naik returned to a fulltime academic position in February 2018, as a professor of medicine at SUNY Upstate Medical University; he served as an Assistant Dean and Director for Clinical and Translational Research Programs at SUNY Upstate Medical University. Subsequently and prior to joining NYU, he was a clinical professor of medicine and Director of Diabetes Clinical Innovation at the University of Washington.
His research areas of interest include autoimmune diabetes, immune interventions in type 1 diabetes, newer therapies in diabetes, and diabetes/technology interaction.
Disclosure information not submitted.
SY27-04 - The Silent Threat: Prediabetes, Cardiovascular Risk, and the Need for Early Action
Sunday, June 14, 2026
11:36 AM - 11:58 AM CT